Su Xian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Su Xian has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Maurizio Zanetti
The Laboratory of Immunology, Department of Medicine and Moores Cancer Center, University of California San Diego
7 shared publications Hannah Carter
4 shared publications- Hannah Carter
Department of Medicine, Division of Medical Genetics, University of California San Diego
4 shared publications - T. Cameron Waller
Mayo Clinic
3 shared publications Alyssa Lew
The Laboratory of Immunology, Department of Medicine and Moores Cancer Center, University of California, San Diego, La Jolla, California, United States of America
2 shared publicationsGonzalo Almanza
The Laboratory of Immunology Department of Medicine and Moores Cancer Center University of California, San Diego La Jolla CA USA
2 shared publications
Latest Publications
- Open Access
- 30 March 2026
- Published by Elsevier in SSRN Electronic Journal
A Germline Variant at the TERT Locus Predicts Intra-Tumor T Cell Exhaustion and Response to Immune Checkpoint Blockade
The role of polymorphic variation in intra-tumor T cells is relatively unexplored. Here we studied a single nucleotide polymorphism (SNP) in the third intron of the TERT gene (rs13167280) that we found to be associated with chromosome 5p and TERT copy number amplification and an increased odds of KRAS mutation in lung cancer (OR = 1.9, FDR = 0.048). SNP rs13167280 is in linkage disequilibrium (LD) with two SNPs (rs33961405 R2 = 0.13 D' = 0.96, rs6897196 R2 = 0.20 D' = 1) reported to regulate telomere length (TL) (p = 3.0e-06 and 2.0e-83, respectively) in blood cells. Here we show that in the presence of the rs13167280 alternate A allele, tumor-infiltrating CD8 T cells had a significantly higher expression of canonical markers of T cell exhaustion (PD1, CTLA4, and TIGIT, FDR < 0.05) and diminished CYT score, and this coincided with significantly reduced immunoediting (p = 0.0356). An analysis of 594 lung cancer patients across six independent cohorts before immune checkpoint blockade (ICB) treatment showed that A allele carriers had significantly higher levels of T cell infiltration (p = 0.03), and a greater overall survival (OS) benefit after ICB therapy than those without the variant (p = 0.032). Mechanistically, we show that rs13167280 alternate A allele in T cells is associated with histone de-methylation, and creates, importantly, a novel high affinity ETS binding motif which drives increased enhancer reporter expression at the sequence level. Collectively, the data support that SNP rs13167280 orchestrates a hitherto unappreciated role in the dysregulation of intratumor T cells where more efficient TL maintenance function mitigates telomere attrition during recurring antigen encounters without compromising their ability to respond to ICB therapy. We propose that a TERT-associated heritable genetic variant modifies immune surveillance in human lung cancer and affects response to immunotherapy.
- 30 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA Germline Variant at the TERT Locus Predicts Intra-Tumor T Cell Exhaustion and Response to Immune Checkpoint Blockade
The role of polymorphic variation in intra-tumor T cells is relatively unexplored. Here we studied a single nucleotide polymorphism (SNP) in the third intron of the TERT gene (rs13167280) that we found to be associated with chromosome 5p and TERT copy number amplification and an increased odds of KRAS mutation in lung cancer (OR = 1.9, FDR = 0.048). SNP rs13167280 is in linkage disequilibrium (LD) with two SNPs (rs33961405 R2 = 0.13 D' = 0.96, rs6897196 R2 = 0.20 D' = 1) reported to regulate telomere length (TL) (p = 3.0e-06 and 2.0e-83, respectively) in blood cells. Here we show that in the presence of the rs13167280 alternate A allele, tumor-infiltrating CD8 T cells had a significantly higher expression of canonical markers of T cell exhaustion (PD1, CTLA4, and TIGIT, FDR < 0.05) and diminished CYT score, and this coincided with significantly reduced immunoediting (p = 0.0356). An analysis of 594 lung cancer patients across six independent cohorts before immune checkpoint blockade (ICB) treatment showed that A allele carriers had significantly higher levels of T cell infiltration (p = 0.03), and a greater overall survival (OS) benefit after ICB therapy than those without the variant (p = 0.032). Mechanistically, we show that rs13167280 alternate A allele in T cells is associated with histone de-methylation, and creates, importantly, a novel high affinity ETS binding motif which drives increased enhancer reporter expression at the sequence level. Collectively, the data support that SNP rs13167280 orchestrates a hitherto unappreciated role in the dysregulation of intratumor T cells where more efficient TL maintenance function mitigates telomere attrition during recurring antigen encounters without compromising their ability to respond to ICB therapy. We propose that a TERT-associated heritable genetic variant modifies immune surveillance in human lung cancer and affects response to immunotherapy.
- Open Access
- 23 September 2024
- Published by Springer Nature in Research Square
Language-model-based patient embedding using electronic health records facilitates phenotyping, disease forecasting, and progression analysis
Current studies regarding the secondary use of electronic health records (EHR) predominantly rely on domain expertise and existing medical knowledge. Though significant efforts have been devoted to investigating the application of machine learning algorithms in the EHR, efficient and powerful representation of patients is needed to unleash the potential of discovering new medical patterns underlying the EHR. Here, we present an unsupervised method for embedding high-dimensional EHR data at the patient level, aimed at characterizing patient heterogeneity in complex diseases and identifying new disease patterns associated with clinical outcome disparities. Inspired by the architecture of modern language models—specifically transformers with attention mechanisms, we use patient diagnosis and procedure codes as vocabularies and treat each patient as a sentence to perform the patient embedding. We applied this approach to 34,851 unique medical codes across 1,046,649 longitudinal patient events, including 102,739 patients from the electronic Medical Records and GEnomics (eMERGE) Network. The resulting patient vectors demonstrated excellent performance in predicting future disease events (median AUROC = 0.87 within one year) and bulk phenotyping (median AUROC = 0.84). We then illustrated the utility of these patient vectors in revealing heterogeneous comorbidity patterns, exemplified by disease subtypes in colorectal cancer and systemic lupus erythematosus, and capturing distinct longitudinal disease trajectories. External validation using EHR data from the University of Washington confirmed robust model performance, with median AUROCs of 0.83 and 0.84 for bulk phenotyping tasks and disease onset prediction, respectively. Importantly, the model reproduced the clustering results of disease subtypes identified in the eMERGE cohort and uncovered variations in overall mortality among these subtypes. Together, these results underscore the potential of representation learning in EHRs to enhance patient characterization and associated clinical outcomes, thereby advancing disease forecasting and facilitating personalized medicine.
- 23 September 2024
- Published by Springer Nature in Research Square
Open AccessLanguage-model-based patient embedding using electronic health records facilitates phenotyping, disease forecasting, and progression analysis
Current studies regarding the secondary use of electronic health records (EHR) predominantly rely on domain expertise and existing medical knowledge. Though significant efforts have been devoted to investigating the application of machine learning algorithms in the EHR, efficient and powerful representation of patients is needed to unleash the potential of discovering new medical patterns underlying the EHR. Here, we present an unsupervised method for embedding high-dimensional EHR data at the patient level, aimed at characterizing patient heterogeneity in complex diseases and identifying new disease patterns associated with clinical outcome disparities. Inspired by the architecture of modern language models—specifically transformers with attention mechanisms, we use patient diagnosis and procedure codes as vocabularies and treat each patient as a sentence to perform the patient embedding. We applied this approach to 34,851 unique medical codes across 1,046,649 longitudinal patient events, including 102,739 patients from the electronic Medical Records and GEnomics (eMERGE) Network. The resulting patient vectors demonstrated excellent performance in predicting future disease events (median AUROC = 0.87 within one year) and bulk phenotyping (median AUROC = 0.84). We then illustrated the utility of these patient vectors in revealing heterogeneous comorbidity patterns, exemplified by disease subtypes in colorectal cancer and systemic lupus erythematosus, and capturing distinct longitudinal disease trajectories. External validation using EHR data from the University of Washington confirmed robust model performance, with median AUROCs of 0.83 and 0.84 for bulk phenotyping tasks and disease onset prediction, respectively. Importantly, the model reproduced the clustering results of disease subtypes identified in the eMERGE cohort and uncovered variations in overall mortality among these subtypes. Together, these results underscore the potential of representation learning in EHRs to enhance patient characterization and associated clinical outcomes, thereby advancing disease forecasting and facilitating personalized medicine.
- Open Access
- 26 October 2021
- Published by Springer Nature in EMBO Reports
- Vol. 22 (12) , e52509
The unfolded protein response links tumor aneuploidy to local immune dysregulation
Aneuploidy is a chromosomal abnormality associated with poor prognosis in many cancer types. Here, we tested the hypothesis that the unfolded protein response (UPR) mechanistically links aneuploidy and local immune dysregulation. Using a single somatic copy number alteration (SCNA) score inclusive of whole-chromosome, chromosome arm, and focal alterations in a pan-cancer analysis of 9,375 samples in The Cancer Genome Atlas (TCGA) database, we found an inverse correlation with a cytotoxicity (CYT) score across disease stages. Co-expression patterns of UPR genes changed substantially between SCNA low and SCNA high groups. Pathway activity scores showed increased activity of multiple branches of the UPR in response to aneuploidy. The PERK branch showed the strongest association with a reduced CYT score. The conditioned medium of aneuploid cells transmitted XBP1 splicing and caused IL-6 and arginase 1 transcription in receiver bone marrow-derived macrophages and markedly diminished the production of IFN-γ and granzyme B in activated human T cells. We propose the UPR as a mechanistic link between aneuploidy and immune dysregulation in the tumor microenvironment.
- 26 October 2021
- Published by Springer Nature in EMBO Reports
- Vol. 22 (12) , e52509
Open AccessThe unfolded protein response links tumor aneuploidy to local immune dysregulation
Aneuploidy is a chromosomal abnormality associated with poor prognosis in many cancer types. Here, we tested the hypothesis that the unfolded protein response (UPR) mechanistically links aneuploidy and local immune dysregulation. Using a single somatic copy number alteration (SCNA) score inclusive of whole-chromosome, chromosome arm, and focal alterations in a pan-cancer analysis of 9,375 samples in The Cancer Genome Atlas (TCGA) database, we found an inverse correlation with a cytotoxicity (CYT) score across disease stages. Co-expression patterns of UPR genes changed substantially between SCNA low and SCNA high groups. Pathway activity scores showed increased activity of multiple branches of the UPR in response to aneuploidy. The PERK branch showed the strongest association with a reduced CYT score. The conditioned medium of aneuploid cells transmitted XBP1 splicing and caused IL-6 and arginase 1 transcription in receiver bone marrow-derived macrophages and markedly diminished the production of IFN-γ and granzyme B in activated human T cells. We propose the UPR as a mechanistic link between aneuploidy and immune dysregulation in the tumor microenvironment.
- Open Access
The unfolded protein response links tumor aneuploidy to local immune dysregulation
Aneuploidy is a chromosomal abnormality associated with poor prognosis in many cancer types. Here we tested the hypothesis that the unfolded protein response (UPR) links mechanistically aneuploidy and local immune dysregulation. Using a single somatic copy-number alteration (SCNA) score inclusive of whole-chromosome, arm and focal chromosome alterations in a pan-cancer analysis of 9,375 samples in The Cancer Genome Atlas (TCGA) database, we found an inverse correlation with a cytotoxicity (CYT) score across disease stages. Co-expression patterns of UPR genes changed substantially between SCNA low and SCNA high groups. Pathway activity scores showed increased activity by multiple branches of the UPR in response to aneuploidy. The PERK branch showed the strongest association with a reduced CYT score. The conditioned medium of aneuploid cells transmitted XBP1 splicing and caused IL-6 and Arginase1 transcription in receiver bone marrow-derived macrophages. We propose the UPR as a mechanistic link between aneuploidy and immune dysregulation in the tumor microenvironment. Statement of Significance: Aneuploidy accumulates over the life of a tumor and is associated with poor prognosis. Tumor progression is also associated with a progressive immune dysregulation. To explain these complex and concurrent disorders we tested the hypothesis that the unfolded protein could represent the link between aneuploidy and a dysregulation of local immunity favoring tumor progression.
Open AccessThe unfolded protein response links tumor aneuploidy to local immune dysregulation
Aneuploidy is a chromosomal abnormality associated with poor prognosis in many cancer types. Here we tested the hypothesis that the unfolded protein response (UPR) links mechanistically aneuploidy and local immune dysregulation. Using a single somatic copy-number alteration (SCNA) score inclusive of whole-chromosome, arm and focal chromosome alterations in a pan-cancer analysis of 9,375 samples in The Cancer Genome Atlas (TCGA) database, we found an inverse correlation with a cytotoxicity (CYT) score across disease stages. Co-expression patterns of UPR genes changed substantially between SCNA low and SCNA high groups. Pathway activity scores showed increased activity by multiple branches of the UPR in response to aneuploidy. The PERK branch showed the strongest association with a reduced CYT score. The conditioned medium of aneuploid cells transmitted XBP1 splicing and caused IL-6 and Arginase1 transcription in receiver bone marrow-derived macrophages. We propose the UPR as a mechanistic link between aneuploidy and immune dysregulation in the tumor microenvironment. Statement of Significance: Aneuploidy accumulates over the life of a tumor and is associated with poor prognosis. Tumor progression is also associated with a progressive immune dysregulation. To explain these complex and concurrent disorders we tested the hypothesis that the unfolded protein could represent the link between aneuploidy and a dysregulation of local immunity favoring tumor progression.
- Open Access
- 10 June 2020
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 18 (6) , e3000687
IRE1α regulates macrophage polarization, PD-L1 expression, and tumor survival
In the tumor microenvironment, local immune dysregulation is driven in part by macrophages and dendritic cells that are polarized to a mixed proinflammatory/immune-suppressive phenotype. The unfolded protein response (UPR) is emerging as the possible origin of these events. Here we report that the inositol-requiring enzyme 1 (IRE1α) branch of the UPR is directly involved in the polarization of macrophages in vitro and in vivo, including the up-regulation of interleukin 6 (IL-6), IL-23, Arginase1, as well as surface expression of CD86 and programmed death ligand 1 (PD-L1). Macrophages in which the IRE1α/X-box binding protein 1 (Xbp1) axis is blocked pharmacologically or deleted genetically have significantly reduced polarization and CD86 and PD-L1 expression, which was induced independent of IFNγ signaling, suggesting a novel mechanism in PD-L1 regulation in macrophages. Mice with IRE1α- but not Xbp1-deficient macrophages showed greater survival than controls when implanted with B16.F10 melanoma cells. Remarkably, we found a significant association between the IRE1α gene signature and CD274 gene expression in tumor-infiltrating macrophages in humans. RNA sequencing (RNASeq) analysis showed that bone marrow–derived macrophages with IRE1α deletion lose the integrity of the gene connectivity characteristic of regulated IRE1α-dependent decay (RIDD) and the ability to activate CD274 gene expression. Thus, the IRE1α/Xbp1 axis drives the polarization of macrophages in the tumor microenvironment initiating a complex immune dysregulation leading to failure of local immune surveillance.
- 10 June 2020
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 18 (6) , e3000687
Open AccessIRE1α regulates macrophage polarization, PD-L1 expression, and tumor survival
In the tumor microenvironment, local immune dysregulation is driven in part by macrophages and dendritic cells that are polarized to a mixed proinflammatory/immune-suppressive phenotype. The unfolded protein response (UPR) is emerging as the possible origin of these events. Here we report that the inositol-requiring enzyme 1 (IRE1α) branch of the UPR is directly involved in the polarization of macrophages in vitro and in vivo, including the up-regulation of interleukin 6 (IL-6), IL-23, Arginase1, as well as surface expression of CD86 and programmed death ligand 1 (PD-L1). Macrophages in which the IRE1α/X-box binding protein 1 (Xbp1) axis is blocked pharmacologically or deleted genetically have significantly reduced polarization and CD86 and PD-L1 expression, which was induced independent of IFNγ signaling, suggesting a novel mechanism in PD-L1 regulation in macrophages. Mice with IRE1α- but not Xbp1-deficient macrophages showed greater survival than controls when implanted with B16.F10 melanoma cells. Remarkably, we found a significant association between the IRE1α gene signature and CD274 gene expression in tumor-infiltrating macrophages in humans. RNA sequencing (RNASeq) analysis showed that bone marrow–derived macrophages with IRE1α deletion lose the integrity of the gene connectivity characteristic of regulated IRE1α-dependent decay (RIDD) and the ability to activate CD274 gene expression. Thus, the IRE1α/Xbp1 axis drives the polarization of macrophages in the tumor microenvironment initiating a complex immune dysregulation leading to failure of local immune surveillance.
- Open Access
- 20 May 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 8348
IRE1α and IGF signaling predict resistance to an endoplasmic reticulum stress-inducing drug in glioblastoma cells
To date current therapies of glioblastoma multiforme (GBM) are largely ineffective. The induction of apoptosis by an unresolvable unfolded protein response (UPR) represents a potential new therapeutic strategy. Here we tested 12ADT, a sarcoendoplasmic reticulum Ca2+ ATPase (SERCA) inhibitor, on a panel of unselected patient-derived neurosphere-forming cells and found that GBM cells can be distinguished into “responder” and “non-responder”. By RNASeq analysis we found that the non-responder phenotype is significantly linked with the expression of UPR genes, and in particular ERN1 (IRE1) and ATF4. We also identified two additional genes selectively overexpressed among non-responders, IGFBP3 and IGFBP5. CRISPR-mediated deletion of the ERN1, IGFBP3, IGFBP5 signature genes in the U251 human GBM cell line increased responsiveness to 12ADT. Remarkably, >65% of GBM cases in The Cancer Genome Atlas express the non-responder (ERN1, IGFBP3, IGFBP5) gene signature. Thus, elevated levels of IRE1α and IGFBPs predict a poor response to drugs inducing unresolvable UPR and possibly other forms of chemotherapy helping in a better stratification GBM patients.
- 20 May 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 8348
Open AccessIRE1α and IGF signaling predict resistance to an endoplasmic reticulum stress-inducing drug in glioblastoma cells
To date current therapies of glioblastoma multiforme (GBM) are largely ineffective. The induction of apoptosis by an unresolvable unfolded protein response (UPR) represents a potential new therapeutic strategy. Here we tested 12ADT, a sarcoendoplasmic reticulum Ca2+ ATPase (SERCA) inhibitor, on a panel of unselected patient-derived neurosphere-forming cells and found that GBM cells can be distinguished into “responder” and “non-responder”. By RNASeq analysis we found that the non-responder phenotype is significantly linked with the expression of UPR genes, and in particular ERN1 (IRE1) and ATF4. We also identified two additional genes selectively overexpressed among non-responders, IGFBP3 and IGFBP5. CRISPR-mediated deletion of the ERN1, IGFBP3, IGFBP5 signature genes in the U251 human GBM cell line increased responsiveness to 12ADT. Remarkably, >65% of GBM cases in The Cancer Genome Atlas express the non-responder (ERN1, IGFBP3, IGFBP5) gene signature. Thus, elevated levels of IRE1α and IGFBPs predict a poor response to drugs inducing unresolvable UPR and possibly other forms of chemotherapy helping in a better stratification GBM patients.
- Open Access
IRE1α regulates macrophage polarization, PD-L1 expression and tumor survival
In the tumor microenvironment local immune dysregulation is driven in part by macrophages and dendritic cells that are polarized to a mixed proinflammatory/immune suppressive phenotype. The unfolded protein response (UPR) is emerging as the possible origin of these events. Here we report that the inositol-requiring enzyme 1 (IRE1α) branch of the UPR is directly involved in the polarization of macrophages in vitro and in vivo, including the upregulation of IL-6, IL-23, Arginase1, as well as surface expression of CD86 and PD-L1. Macrophages in which the IRE1α/Xbp1 axis is blocked pharmacologically or deleted genetically have significantly reduced polarization, and CD86 and PD-L1 expression, which was induced independent of IFNγ signaling suggesting a novel mechanism in PD-L1 regulation in macrophages. Mice with IRE1α- but not Xbp1-deficient macrophages showed greater survival than controls when implanted with B16.F10 melanoma cells. Remarkably, we found a significant association between the IRE1α gene signature and CD274 gene expression in tumor-infiltrating macrophages in humans. RNASeq analysis showed that bone marrow derived macrophages with IRE1α deletion lose the integrity of the gene connectivity characteristic of regulated IRE1α-dependent decay (RIDD) and the ability to activate CD274 gene expression. Thus, the IRE1α/Xbp1 axis drives the polarization of macrophages in the tumor microenvironment initiating a complex immune dysregulation leading to failure of local immune surveillance.
Open AccessIRE1α regulates macrophage polarization, PD-L1 expression and tumor survival
In the tumor microenvironment local immune dysregulation is driven in part by macrophages and dendritic cells that are polarized to a mixed proinflammatory/immune suppressive phenotype. The unfolded protein response (UPR) is emerging as the possible origin of these events. Here we report that the inositol-requiring enzyme 1 (IRE1α) branch of the UPR is directly involved in the polarization of macrophages in vitro and in vivo, including the upregulation of IL-6, IL-23, Arginase1, as well as surface expression of CD86 and PD-L1. Macrophages in which the IRE1α/Xbp1 axis is blocked pharmacologically or deleted genetically have significantly reduced polarization, and CD86 and PD-L1 expression, which was induced independent of IFNγ signaling suggesting a novel mechanism in PD-L1 regulation in macrophages. Mice with IRE1α- but not Xbp1-deficient macrophages showed greater survival than controls when implanted with B16.F10 melanoma cells. Remarkably, we found a significant association between the IRE1α gene signature and CD274 gene expression in tumor-infiltrating macrophages in humans. RNASeq analysis showed that bone marrow derived macrophages with IRE1α deletion lose the integrity of the gene connectivity characteristic of regulated IRE1α-dependent decay (RIDD) and the ability to activate CD274 gene expression. Thus, the IRE1α/Xbp1 axis drives the polarization of macrophages in the tumor microenvironment initiating a complex immune dysregulation leading to failure of local immune surveillance.
- Open Access
- 6 February 2020
- Published by Springer Nature in Blood Cancer Journal
- Vol. 10 (2) , 1-14
The RUNX1-ETO target gene RASSF2 suppresses t(8;21) AML development and regulates Rac GTPase signaling
Large-scale chromosomal translocations are frequent oncogenic drivers in acute myeloid leukemia (AML). These translocations often occur in critical transcriptional/epigenetic regulators and contribute to malignant cell growth through alteration of normal gene expression. Despite this knowledge, the specific gene expression alterations that contribute to the development of leukemia remain incompletely understood. Here, through characterization of transcriptional regulation by the RUNX1-ETO fusion protein, we have identified Ras-association domain family member 2 (RASSF2) as a critical gene that is aberrantly transcriptionally repressed in t(8;21)-associated AML. Re-expression of RASSF2 specifically inhibits t(8;21) AML development in multiple models. Through biochemical and functional studies, we demonstrate RASSF2-mediated functions to be dependent on interaction with Hippo kinases, MST1 and MST2, but independent of canonical Hippo pathway signaling. Using proximity-based biotin labeling we define the RASSF2-proximal proteome in leukemia cells and reveal association with Rac GTPase-related proteins, including an interaction with the guanine nucleotide exchange factor, DOCK2. Importantly, RASSF2 knockdown impairs Rac GTPase activation, and RASSF2 expression is broadly correlated with Rac-mediated signal transduction in AML patients. Together, these data reveal a previously unappreciated mechanistic link between RASSF2, Hippo kinases, and Rac activity with potentially broad functional consequences in leukemia.
- 6 February 2020
- Published by Springer Nature in Blood Cancer Journal
- Vol. 10 (2) , 1-14
Open AccessThe RUNX1-ETO target gene RASSF2 suppresses t(8;21) AML development and regulates Rac GTPase signaling
Large-scale chromosomal translocations are frequent oncogenic drivers in acute myeloid leukemia (AML). These translocations often occur in critical transcriptional/epigenetic regulators and contribute to malignant cell growth through alteration of normal gene expression. Despite this knowledge, the specific gene expression alterations that contribute to the development of leukemia remain incompletely understood. Here, through characterization of transcriptional regulation by the RUNX1-ETO fusion protein, we have identified Ras-association domain family member 2 (RASSF2) as a critical gene that is aberrantly transcriptionally repressed in t(8;21)-associated AML. Re-expression of RASSF2 specifically inhibits t(8;21) AML development in multiple models. Through biochemical and functional studies, we demonstrate RASSF2-mediated functions to be dependent on interaction with Hippo kinases, MST1 and MST2, but independent of canonical Hippo pathway signaling. Using proximity-based biotin labeling we define the RASSF2-proximal proteome in leukemia cells and reveal association with Rac GTPase-related proteins, including an interaction with the guanine nucleotide exchange factor, DOCK2. Importantly, RASSF2 knockdown impairs Rac GTPase activation, and RASSF2 expression is broadly correlated with Rac-mediated signal transduction in AML patients. Together, these data reveal a previously unappreciated mechanistic link between RASSF2, Hippo kinases, and Rac activity with potentially broad functional consequences in leukemia.
- Open Access
- 25 July 2019
- Published by Springer Nature in BMC Medical Genomics
- Vol. 12 (S6) , 1-13
Elevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes
The major histocompatibility complex class I (MHC-I) molecule is a protein complex that displays intracellular peptides to T cells, allowing the immune system to recognize and destroy infected or cancerous cells. MHC-I is composed of a highly polymorphic HLA-encoded alpha chain that binds the peptide and a Beta-2-microglobulin (B2M) protein that acts as a stabilizing scaffold. HLA mutations have been implicated as a mechanism of immune evasion during tumorigenesis, and B2M is considered a tumor suppressor gene. However, the implications of somatic HLA and B2M mutations have not been fully explored in the context of antigen presentation via the MHC-I molecule during tumor development. To understand the effect that B2M and HLA MHC-I molecule mutations have on mutagenesis, we analyzed the accumulation of mutations in patients from The Cancer Genome Atlas according to their MHC-I molecule mutation status. Somatic B2M and HLA mutations in microsatellite stable tumors were associated with higher overall mutation burden and a larger fraction of HLA-binding neoantigens when compared to B2M and HLA wild type tumors. B2M and HLA mutations were highly enriched in patients with microsatellite instability. B2M mutations tended to occur relatively early during patients’ respective tumor development, whereas HLA mutations were either early or late events. In addition, B2M and HLA mutated patients had higher levels of immune infiltration by natural killer and CD8+ T cells and higher levels of cytotoxicity. Our findings add to a growing body of evidence that somatic B2M and HLA mutations are a mechanism of immune evasion by demonstrating that such mutations are associated with a higher load of neoantigens that should be presented via MHC-I.
- 25 July 2019
- Published by Springer Nature in BMC Medical Genomics
- Vol. 12 (S6) , 1-13
Open AccessElevated neoantigen levels in tumors with somatic mutations in the HLA-A, HLA-B, HLA-C and B2M genes
The major histocompatibility complex class I (MHC-I) molecule is a protein complex that displays intracellular peptides to T cells, allowing the immune system to recognize and destroy infected or cancerous cells. MHC-I is composed of a highly polymorphic HLA-encoded alpha chain that binds the peptide and a Beta-2-microglobulin (B2M) protein that acts as a stabilizing scaffold. HLA mutations have been implicated as a mechanism of immune evasion during tumorigenesis, and B2M is considered a tumor suppressor gene. However, the implications of somatic HLA and B2M mutations have not been fully explored in the context of antigen presentation via the MHC-I molecule during tumor development. To understand the effect that B2M and HLA MHC-I molecule mutations have on mutagenesis, we analyzed the accumulation of mutations in patients from The Cancer Genome Atlas according to their MHC-I molecule mutation status. Somatic B2M and HLA mutations in microsatellite stable tumors were associated with higher overall mutation burden and a larger fraction of HLA-binding neoantigens when compared to B2M and HLA wild type tumors. B2M and HLA mutations were highly enriched in patients with microsatellite instability. B2M mutations tended to occur relatively early during patients’ respective tumor development, whereas HLA mutations were either early or late events. In addition, B2M and HLA mutated patients had higher levels of immune infiltration by natural killer and CD8+ T cells and higher levels of cytotoxicity. Our findings add to a growing body of evidence that somatic B2M and HLA mutations are a mechanism of immune evasion by demonstrating that such mutations are associated with a higher load of neoantigens that should be presented via MHC-I.